Capricor Therapeutics Current Debt
| CAPR Stock | USD 5.24 0.09 1.69% |
Capricor Therapeutics holds a debt-to-equity ratio of 0.146. At this time, Capricor Therapeutics' Long Term Debt is relatively stable compared to the past year. As of 05/03/2024, Long Term Debt Total is likely to grow to about 4.9 M, while Short and Long Term Debt Total is likely to drop slightly above 4 M. Capricor Therapeutics' financial risk is the risk to Capricor Therapeutics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Capricor Therapeutics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Capricor Therapeutics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Capricor Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Capricor Therapeutics' stakeholders.
For most companies, including Capricor Therapeutics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for the executing running Capricor Therapeutics the most critical issue when dealing with liquidity needs is whether the current assets are properly aligned with its current liabilities. If not, management will need to obtain alternative financing to ensure that there are always enough cash equivalents on the balance sheet in reserve to pay for obligations.
Price Book 8.7115 | Book Value 0.726 | Operating Margin (0.11) | Profit Margin (0.89) | Return On Assets (0.28) |
Given that Capricor Therapeutics' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Capricor Therapeutics is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Capricor Therapeutics to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Capricor Therapeutics is said to be less leveraged. If creditors hold a majority of Capricor Therapeutics' assets, the Company is said to be highly leveraged.
At this time, Capricor Therapeutics' Long Term Debt is relatively stable compared to the past year. As of 05/03/2024, Long Term Debt Total is likely to grow to about 4.9 M, while Short and Long Term Debt Total is likely to drop slightly above 4 M. Capricor |
Capricor Therapeutics Financial Leverage Rating
Capricor Therapeutics bond ratings play a critical role in determining how much Capricor Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Capricor Therapeutics' borrowing costs.Capricor Therapeutics Debt to Cash Allocation
As Capricor Therapeutics follows its natural business cycle, the capital allocation decisions will not magically go away. Capricor Therapeutics' decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors. Many companies eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
The company currently holds 5.61 M in liabilities with Debt to Equity (D/E) ratio of 0.15, which may suggest the company is not taking enough advantage from borrowing. Capricor Therapeutics has a current ratio of 2.64, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Capricor Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Capricor Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Capricor Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Capricor to invest in growth at high rates of return. When we think about Capricor Therapeutics' use of debt, we should always consider it together with cash and equity.Capricor Therapeutics Total Assets Over Time
Capricor Therapeutics Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Capricor Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Capricor Therapeutics, which in turn will lower the firm's financial flexibility. Like all other financial ratios, a a Capricor Therapeutics debt ratio should be compared their industry average or other competing firms.Capricor Net Debt
Understaning Capricor Therapeutics Use of Financial Leverage
Capricor Therapeutics financial leverage ratio helps in determining the effect of debt on the overall profitability of the company. It measures Capricor Therapeutics's total debt position, including all of outstanding debt obligations, and compares it with the equity. In simple terms, the high financial leverage means the cost of production, together with running the business day-to-day, is high, whereas, lower financial leverage implies lower fixed cost investment in the business and generally considered by investors to be a good sign. So if creditors own a majority of Capricor Therapeutics assets, the company is considered highly leveraged. Understanding the composition and structure of overall Capricor Therapeutics debt and outstanding corporate bonds gives a good idea of how risky the capital structure of a business and if it is worth investing in it. Financial leverage can amplify the potential profits to Capricor Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Capricor Therapeutics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets).
| Last Reported | Projected for Next Year | ||
| Net Debt | -9.1 M | -8.6 M | |
| Short and Long Term Debt Total | 5.6 M | 4 M | |
| Short Term Debt | 749.1 K | 711.7 K | |
| Long Term Debt | 3 M | 3.7 M | |
| Long Term Debt Total | 3 M | 4.9 M | |
| Short and Long Term Debt | 222 K | 210.9 K | |
| Net Debt To EBITDA | 0.39 | 0.41 | |
| Debt To Equity | 0.18 | 0.19 | |
| Interest Debt Per Share | 0.15 | 0.15 | |
| Debt To Assets | 0.07 | 0.07 | |
| Long Term Debt To Capitalization | 0.13 | 0.12 | |
| Total Debt To Capitalization | 0.15 | 0.16 | |
| Debt Equity Ratio | 0.18 | 0.19 | |
| Debt Ratio | 0.07 | 0.07 | |
| Cash Flow To Debt Ratio | (6.20) | (6.51) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Capricor Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Capricor Therapeutics' short interest history, or implied volatility extrapolated from Capricor Therapeutics options trading.
Pair Trading with Capricor Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Capricor Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Capricor Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Capricor Stock
| 0.7 | IMRX | Immuneering Corp Earnings Call This Week | PairCorr |
| 0.69 | EDSA | Edesa Biotech Financial Report 9th of May 2024 | PairCorr |
| 0.66 | IMCR | Immunocore Holdings Financial Report 8th of May 2024 | PairCorr |
| 0.57 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.56 | TXG | 10X Genomics | PairCorr |
The ability to find closely correlated positions to Capricor Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Capricor Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Capricor Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Capricor Therapeutics to buy it.
The correlation of Capricor Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Capricor Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Capricor Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Capricor Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Capricor Therapeutics Fundamentals Over Time. To learn how to invest in Capricor Stock, please use our How to Invest in Capricor Therapeutics guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Capricor Stock analysis
When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
Is Capricor Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Capricor Therapeutics. If investors know Capricor will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Capricor Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.83) | Revenue Per Share 0.94 | Quarterly Revenue Growth 11.593 | Return On Assets (0.28) | Return On Equity (1.30) |
The market value of Capricor Therapeutics is measured differently than its book value, which is the value of Capricor that is recorded on the company's balance sheet. Investors also form their own opinion of Capricor Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Capricor Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Capricor Therapeutics' market value can be influenced by many factors that don't directly affect Capricor Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Capricor Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Capricor Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Capricor Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.